BioCryst to Announce Third Quarter 2013 Financial Results November 5

  BioCryst to Announce Third Quarter 2013 Financial Results November 5

Business Wire

RESEARCH TRIANGLE PARK, N.C. -- October 23, 2013

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its third
quarter 2013 financial results will be released on Tuesday, November 5, 2013.
BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to
discuss the financial results and to provide an update on the Company’s
programs. The call will be led by Jon P. Stonehouse, President and Chief
Executive Officer, Thomas R. Staab, II, Senior Vice President and Chief
Financial Officer and Dr. William P. Sheridan, Senior Vice President and Chief
Medical Officer.

Links to a live audio webcast and replay of the presentation may be accessed
on the BioCryst website events page at
http://investor.shareholder.com/biocryst/events.cfm.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule
drugs that block key enzymes involved in infectious and inflammatory diseases,
with the goal of addressing unmet medical needs of patients and physicians.
BioCryst’s core development programs include BCX4161 and a next generation
oral inhibitor of plasma kallikrein for hereditary angioedema; peramivir, a
viral neuraminidase inhibitor for the treatment of influenza; and BCX4430, a
broad spectrum antiviral for hemorrhagic fevers. For more information, please
visit the Company's website at www.BioCryst.com.

This press release contains forward-looking statements, including statements
regarding future results and achievements. These statements involve known and
unknown risks, uncertainties and other factors which may cause our actual
results, performance or achievements to be materially different from any
future results, performances or achievements expressed or implied by the
forward-looking statements. Please refer to the documents BioCryst files
periodically with the SEC and located at
http://investor.shareholder.com/biocryst/sec.cfm.

BCRXW

Contact:

BioCryst Pharmaceuticals
Robert Bennett, +1-919-859-7910